AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication

AstraZeneca (AZN) announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of Truqap (capivasertib) for the treatment of castration-resistant prostate cancer (CRPC) in patients with PTEN deficiency. The approval is based on phase III trial data demonstrating improved progression-free survival.

The Product

Truqap is an oral, selective AKT inhibitor targeting the PI3K/AKT pathway, which is often hyperactive in PTEN-deficient tumors. The phase III trial showed that adding Truqap to abiraterone therapy improved outcomes compared to placebo.

Pricing and Availability

AstraZeneca has not yet disclosed pricing or commercial launch dates. The product is expected to become available in the coming months following final regulatory steps.

Competition

Truqap competes with other CRPC treatments like enzalutamide and apalutamide, but its molecular targeting of PTEN-deficient patients—a subset representing about 20-30% of prostate cancer cases—provides a unique differentiation.

Potential Impact on the Company

This approval significantly expands Truqap's label, previously approved for breast cancer. It is expected to boost AstraZeneca's oncology revenue, a key growth driver for the company.